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Abstract: 35 
Virus infections cause diseases of different severity ranged from mild infection e.g. common 36 
cold into life threating diseases e.g. Human Immunodeficiency virus (HIV), Hepatitis B. Virus 37 
infections represent 44% of newly emerging infections. Although there are many efficient 38 
antiviral agents, they still have drawbacks due to accumulation at off target organs and 39 
developing of virus resistance due to virus mutation. Therefore, developing a delivery system 40 
that can selectively target drug into affected organs and avoid off target accumulation would 41 
be a highly advantageous strategy to improve antiviral therapy. Nanoparticles (NP) can be 42 
effectively targeted to the liver, and therefore it could be used for improving therapy of hepatic 43 
virus infections including hepatitis B virus and hepatitis C virus (HCV). Many studies were 44 
performed to encapsulate antiviral agents into nano-delivery system to improve their 45 
pharmacokinetics parameters to have a better therapeutic efficacy with lower side effects. 46 
However, the effect of virus infection on the uptake of NP has not yet been studied in detail. 47 
The latter is a crucial area as modulation of endocytic uptake of nanoparticles could impact on 48 
reduce potential therapeutic usefulness of antiviral agents loaded into nano-delivery system. In 49 
this study, a fluorescently-labelled polymeric nanoparticle was prepared and used to track NP 50 
uptake into Huh7.5, human hepatoma cells transfected with replicating HCV genomes, 51 
compared with non-transfected cells as a model representing hepatocyte uptake. Confocal 52 
microscopy and flow cytometry of virus transfected Huh7.5 cells unexpectedly demonstrated 53 
two-fold increase in uptake of NP compared to non-transfected cells. Therefore, virus 54 
transfection enhanced NP uptake into Huh7.5 cells and NP could be considered as a promising 55 
delivery system for targeted treatment of  hepatitis viruses..  56 
 57 
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Introduction:  59 
Emerging infectious diseases (EID) present a considerable threat to human life on earth. 60 
Viruses are the largest and most genetically diverse biomass on earth (Suttle, 2005) and account 61 
for 44% of EID (Taylor et al., 2001). Itaya virus, Iquitos virus, Ngari virus and Ilesha virus that 62 
are new emerging viruses in South America and East Africa (Wiwanitkit and Wiwanitkit, 63 
2015), chikungunya virus has spread worldwide (Rothan et al., 2016), and Zika virus is now a 64 
major global health threat (Lazear and Diamond, 2016); (Paixão et al., 2016). 65 
Emerging viruses therefore present a major public health and therapeutic challenge. 66 
Fortunately, it is known that viruses belonging to the same family, share similar characteristics 67 
(King et al., 2012). This allows many newly emerged viruses to be treated with established 68 
Food and Drug Administration (FDA) approved antiviral agents (Tan et al., 2017); (Yeo et al., 69 
2015). Currently, there are around 90 active antiviral drugs approved for the effective treatment 70 
of many types of virus infections (Clercq, 2016). However, their administration is accompanied 71 
by side effects that can limit their potential use. E.g. ribavirin causes haemolytic anaemia 72 
(Hutchison et al., 2002), while other agents, including zidovudine, zalcitabine, lamivudine, and 73 
abacavir may give rise to peripheral neuropathy, leukopenia, pancreatitis, gout and life-74 
threatening hypersensitivity reactions (Montessori et al., 2004). Development of antiviral 75 
resistance due to virus mutation is an additional problem (Lembo et al., 2018). Side effects are 76 
commonly due to accumulation of antiviral drug into off-target organs and therefore, finding a 77 
way that could selectively deliver antiviral agents into the target organ whilst avoiding, or 78 
reducing off-target accumulation is highly desirable and could improve the specificity and 79 
efficacy of antiviral therapy. Nano-delivery systems are known to modify the physicochemical 80 
properties e.g solubility and pharmacokinetics parameters (absorption, distribution, 81 
metabolism and elimination) of the encapsulated materials via controlled drug release.  They 82 
can also be tailored for passive (e.g. controlling particle size) or active (surface decoration with 83 
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ligands) targeting of the therapeutic agents. Consequently, using a nano-delivery system for 84 
antiviral therapy could result in a lower dose of antiviral agents and a reduced side effect profile  85 
(Lembo et al., 2018). Nowacek and colleagues (Nowacek et al., 2012) prepared nanocrystals 86 
(a nano-sized delivery system composed of 100% drug with no carrier) of antiretroviral agents 87 
(Indinavir, Ritonavir, Atazanavir, and Efavirenz) as a way to improve their antiviral potency 88 
against HIV. In vitro study showed that nanocrystals improved cellular uptake into monocyte-89 
derived macrophage (phagocytic cells) and reduced cytotoxicity compared to the free parent 90 
drug. All nanocrystals showed antiretroviral activity ranging from 20% to 100%, depending on 91 
the formulation and drug type (Nowacek et al., 2012). Although many studies have been 92 
concerned with improvement of antiviral potency and trying to reduce its side effects via 93 
encapsulation into nano-delivery system, the effect of virus infection on the uptake of NP into 94 
host cells has not been studied in detail.  A down-regulation of endocytosis by virus would 95 
make NP delivery of the appropriate antiviral agent(s) less effective, whereas upregulation of 96 
endocytosis in infected cells could facilitate targeted uptake of drug into infected cells and 97 
further reduce side effects.  98 
In order to address this important question, we used an established in vitro model of hepatitis 99 
C virus (HCV) replication to interrogate the capacity of virus infection to modulate uptake of 100 
NP. Therefore, in the current study, a fluorescently labelled polymer NP, Rhodamine B 101 
isothiocyanate (RBITC) labelled NP prepared with the bio-compatible polymer, poly(glycerol-102 
adipate) [PGA] have been used in combination with Huh7.5 cells (non-phagocytic cells) 103 
transfected with hepatitis C virus (J6/JFH1 chimera) to track how virus infection could 104 
modulate the endocytic uptake of NP. Huh7.5 cells and the J6/JFH1 chimera  have been used 105 
in the current study because it was reported that Huh7.5 cells are highly permissive to HCV 106 
infection (Lanford et al., 2003); (Sumpter et al., 2005)  and the J6/JFH1 chimera (HCV RNA) 107 
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is considered as the most efficient replicating chimera in Huh7.5 cells (Lindenbach et al., 108 
2005). 109 
2. Materials and Methods: 110 
2.1. Materials: 111 
All materials were purchased from Sigma-Aldrich and VWR and used as supplied except for 112 
divinyladipate purchased from Tokyo Chemical Industry UK Ltd. Huh7.5, hepatocellular 113 
carcinoma cells were supplied by Apath LLC. Phenol red free - Dulbecco's Modified Eagle 114 
Medium (DMEM), foetal bovine serum (FBS), non-essential amino acids (NEAA), penicillin, 115 
streptomycin, C7-50, mouse anti-HCV core protein antibody (primary antibody) and Alexa-116 
488, anti-mouse IgG antibody (secondary antibody) were supplied by Thermo Fisher.   117 
2.2. Methods: 118 
2.2.1. Synthesis and characterisation of Poly(Glycerol adipate): 119 
PGA is a functionalized linear polyester. It was synthesized and characterised as previously 120 
reported (Kallinteri et al., 2005); (Taresco et al., 2016). In brief, PGA was Enzymatically 121 
synthesized where equal amounts (250 mmol) of glycerol and DVA were dissolved in dry 122 
tetrahydrofuran (THF, 30 ml) in presence of a catalytic enzyme, Novozyme 435 (1.25 gm) and 123 
the reaction was stirred (overhead stirrer, 200 rpm) at constant temp (50 ̊ C) for 24h. This was 124 
followed by enzyme filtration and evaporation of THF to obtain a yellowish jelly-like polymer. 125 
 126 
2.2.2. Preparation of fluorescently labelled nanoparticles: 127 
RBITC PGA NP were prepared by an interfacial deposition method as reported (Meng et al., 128 
2006) with the following modifications; RBITC (200 µl, 1 mg/ml, methanol) was added into 129 
the aqueous phase (HEPES buffer, 10 mM, pH 7.4, 7ml). The polymer (20mg) dissolved in 130 
acetone (2ml) was added dropwise into the aqueous phase while stirring. The organic solvent 131 
was evaporated overnight. RBITC PGA NP were purified by loading the sample onto a 132 
Sepharose CL-4B gel column (C2.5 X 40, Pharmacia, bed volume 91ml). The column was 133 
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eluted by water using a peristaltic pump at a flow rate of 1 ml/min and collected in fractions, 134 
1.5ml/ tube. The peaks of dye labelled NP and free dye were detected using a Pharmacia 135 
chromatographic UV detector (206nm filter). The purified NP dispersion was collected and 136 
characterized using a Malvern Zetasizer Nano ZS (Malvern Instruments Ltd, Malvern, UK) at 137 
25 °C ± 0.1. Particle size and zeta potential were measured in HEPES buffer (1 mM, pH 7.4)  138 
The dye loading, and encapsulation percentages were determined by a direct method. A 139 
weighed amount of freeze dried RBITC PGA NP was extracted by acetone: methanol (1:1) and 140 
dye fluorescence was measured at λEx, 545 nm and λEm, 575 nm. Then the concentration of dye 141 
was determined from the calibration curve of known dye concentrations in acetone: methanol 142 
(1:1) using a spectrophotofluorometer (Hitachi F-4500 Hitachi, place), with slit widths adjusted 143 
to 5 nm.  144 
2.2.3. Stabilization of NP in physiological buffer: 145 
Either surfactants or human plasma were used to stabilize the RBITC PGA NP to physiological 146 
salt concentrations, (1) polysorbate surfactants (Tween 80/Tween 20) were either added to give 147 
a final concentrations 0.01% and 0.1% v/v to the pre-prepared NP (100 µl, 100 µg), or during 148 
NP preparation (in situ addition).  (2) Alternatively, freshly isolated human plasma (100 µl) 149 
was incubated with NP (100 µl, 100 µg) for 5 minutes or 24 h before addition of phosphate 150 
buffered saline (PBS).  151 
To investigate how PBS affects NP stability, RBITC PGA NP (100 µl, 100 µg) were diluted 152 
with PBS followed by particle size measurement in PBS. The final volume for all the previous 153 
samples was adjusted to 1 ml using PBS. For particle stability measurement, NP (100 µl) were 154 
diluted with HEPES buffer (1 mM, pH 7.4) to 1 ml and used as a control for NP size. Particle 155 
size measurements were performed using the Malvern Zetasizer Nano ZS.  156 
  157 
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2.2.4. Investigation of NP uptake by HCV virus transfected/non-transfected Huh7.5 cells:  158 
Huh7.5 cells (8 x 106) were electroporated in cytomix buffer (400 µl) [potassium chloride (120 159 
mM), calcium chloride (0.15 mM), di-potassium phosphate/ Mono-potassium phosphate (10 160 
mM, pH 7.6)] in the absence (non-transfected cells) or presence (transfected cells) of a 10 μg 161 
of J6/JFH1 HCV chimeric RNA at 220V/22ms. Cells were then incubated in phenol red free - 162 
DMEM containing 10% FBS, penicillin (100 U/ml), streptomycin (100 μg/ml), and 1% NEAA 163 
for 24 hours at 37 ̊ C and 5% CO2.  164 
For confocal microscopy, 5 x 104 of the previously electroporated cells (either virus transfected 165 
or non-transfected cells) were added to wells of a 24-well cluster (Nunclon; Nunc) containing 166 
glass cover slips. Cells were incubated for another 24 hours with phenol red free - DMEM (1 167 
ml) followed by washing with PBS (1ml X 3). Phenol red free - DMEM (0.8 ml) and NP 168 
stabilised with FBS (100 g, 200 l) were added to these cells followed by incubation at 37 ̊ C 169 
and 5% CO2 for different time intervals. Cells were washed with PBS, fixed using 170 
paraformaldehyde, and then permeabilized with 0.5% TritonX-100 (400 μl) for 5 minutes. 171 
Virus core protein staining was carried out by addition of mAb C7-50 (1 µg/ml; Thermo Fisher) 172 
in PBS containing 5% FBS and incubated at room temperature (RT) for 45 minutes, followed 173 
by PBS wash (400 μl X 3). Cells were then incubated with Alexa-488 anti-mouse IgG (2 µg/ml) 174 
in 5% FBS in PBS for 60 min at RT and washed three times with PBS. Cell nuclei were stained 175 
by incubation of 5 µM 4', 6-diamidino-2-phenylindole (DAPI) in PBS with cells for 2-3 176 
minutes at RT followed by three washes with PBS. To investigate the efficiency of virus core 177 
protein expression, a set of virus transfected /non-transfected Huh7.5 cells that were not treated 178 
with NP were prepared and processed under similar conditions, and imaged by fluorescence 179 
microscopy (Leica DMRB).   180 
 181 
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For flow cytometry quantitative studies, the previously electroporated cells (1 x 105/well) either 182 
transfected or non-transfected were loaded onto 6 wells plate and incubated for another 24h. 183 
Cells were washed three times with PBS. Then, phenol red free - DMEM (3.2ml) and NP/FBS 184 
mixture, (400µg, 800µl) were added into cells followed by incubation at 37 ̊ C and 5% CO2. A 185 
set of control cells was incubated with free RBITC (5 ng, equivalent to the dye amount that 186 
might leak from RBITC PGA NP). After incubation for periods up to 4h, cells were washed 187 
three times with PBS. Cells were detached and fixed with a mixture of 4% paraformaldehyde 188 
and trypsin/EDTA (1:1) and transferred to flow cytometry tubes. Virus transfected cells were 189 
washed twice with 1% FBS in PBS (2 ml, then 1 ml) followed by centrifugation (300 g, 5 min) 190 
to remove the washing solution. Then, cells were permeabilised with PBS containing 1% FBS 191 
and 0.04% saponin (1 ml) before removal of saponin solution by centrifugation (300 g, 5 min). 192 
Cells were stained for virus core protein by incubation with C7-50 (40µg/ml) for 45 minutes at 193 
RT, washed with the saponin mixture again and incubated with anti-mouse IgG Alexa-488 194 
(80µg/ml) for 1h at RT. Cells were washed again with the saponin mixture (1ml) and suspended 195 
in 4% paraformaldehyde. The mean fluorescence intensity (MFI) was determined using a 196 
Beckman Coulter Moflo XPD flow cytometer. Another set of virus transfected cells were 197 
incubated with NP for 4h without staining for virus to assess the possibility that 198 
permeabilization step using saponin may lead to NP release from cells. NP uptake into virus 199 
non-transfected cells was determined similarly to transfected cells but without addition of C7-200 
50 and Alexa-488-secondary antibody. All samples were analysed in triplicate. 201 
 202 
2.2.5. Statistical analysis: Statistical analysis (Two Way ANOVA) were carried out using 203 
SPSS version 21 at 95% confidence interval. 204 
 205 
  206 
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3. Results and Discussion: 207 
3.1. Synthesis and characterization of PGA: The identity of PGA polymer was confirmed 208 
by 1H-NMR (data not shown), and size exclusion chromatography analysis gave an estimated 209 
Mn,SEC = 11.6 KDa and molecular weight dispersity Ð of 1.4 and molecular weight (Mw) = 16 210 
KDa.  211 
3.2. Preparation and characterization of nanoparticles: 212 
RBITC PGA NP were prepared by a nanoprecipitation method. NP with a size around 110 nm 213 
were produced (Table 1) and had a good encapsulation efficiency percentage. Although zeta 214 
potential values indicated that particles should be stable in low ionic strength media, further 215 
investigations were carried out to ensure the particles did not aggregate under relevant 216 
physiological conditions in (see section 3.3).  217 
*PdI = polydispersity index, **% Load = [(Encapsulated dye weight/ NP weight) * 100]    218 
*** % Encapsulation = [(Encapsulated dye weight/ Initial dye weight) * 100].  219 
RBITC PGA NP was used in the current study to track the virus effect on the NP uptake into 220 
Huh7.5 cells for several reasons, (1) RBITC dye is more stable than fluorescein to quenching 221 
by light and fluorescence is improved in the acidic pH of the lysosomal compartment (Garnett 222 
and Baldwin, 1986). (2) RBITC labelled PGA NP retain their dye label for prolonged periods 223 
and so reduce possible artefacts in uptake studies as was demonstrated earlier in our group 224 
(Meng et al., 2006) (3) The initial RBITC released from NP in culture medium over 24h was 225 
very low (4.5%) (Meng et al., 2006) (4) Polymer biocompatibility and biodegradability is 226 
important to be considered for the future therapy of polymer based nano-delivery system. The 227 
Table 1: Physicochemical characterization of RBITC PGA NP: 
Name Particle Size 
(dnm ± SD) *[PdI] 
Zeta Potential 
(mv ± SD) 
**% Load % 
(w/w) ± SD 
***Encapsulation      
Efficiency % ± SD 
RBITC PGA NP 110 ± 30[0.01] - 53.7 ± 13.34 0.54 ± 0.13 54 ± 13 
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degradation by-products of PGA are adipic acid and glycerol which are safe compounds as 228 
approved by FDA (Zhang et al., 2014) (5) The cytotoxicity of PGA has been determined earlier 229 
in our group (Kallinteri et al., 2005), and it showed a very low cell toxicity against Human 230 
Leukaemia cell line, HL60 cell and Human liver cell lines, HepG2 cells at the top dose of 231 
polymer NP, 100 times more of polymer amount required for a therapeutic nano-delivery 232 
system. Also, Navarro and his colleagues (Navarro et al., 2017) have used PGA elastomer and 233 
it was demonstrated to be non-cytotoxic to embryonic mouse fibroblasts (NIH/3T3) after 234 
seeding cells for 6 hours over PGA discs .  235 
3.3. Particle stabilization in physiological buffer: 236 
Particles incubated with PBS showed a high level of aggregation, (Figure 1). Although different 237 
concentrations of polysorbate surfactants were used as potential stabilisers, they were not 238 
accompanied by any improvement of particle stability (data not shown). However, 24h 239 
incubation with human plasma stabilized particles successfully in PBS, resulting in particle 240 
sizes ranging from 237 to 300 nm in diameter (Figure 1). A small peak of higher particle size 241 
in DLS (data not shown) was noted indicating some aggregate formation (representing 14% of 242 
low particle size peak by intensity). 243 
The stability of NP in biological systems is an important consideration, as particles in solutions 244 
with physiological salt concentrations and pH values can form micrometer-sized coarse 245 
agglomerates (Deguchi et al., 2007); (Murdock et al., 2008). Coarse agglomerates of NP will 246 
behave differently in a biological system compared to well-dispersed NP, especially with 247 
respect to endocytic uptake of particles (Buford et al., 2007).  The effectiveness of human 248 
plasma in preventing aggregation could be explained by adsorption of protein molecules onto 249 
the NP surface forming a protein corona (Lynch and Dawson, 2008) that is able to prevent 250 
particle aggregation (Gebauer et al., 2012). The improvement of NP stabilization after 24h 251 
incubation with human plasma might be due to a better and more efficient coating of NP by 252 
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plasma protein that was not achieved by a short incubation. This suggested a relatively slow 253 
adsorption or slow equilibration process of plasma protein adsorption onto the surface of NP 254 
(Casals et al., 2010). This is consistent with the study of Bihari et al, who demonstrated that 255 
human, bovine and mouse serum albumins offered a better stability than Tween 80 for different 256 
types of NP, TiO2 (rutile), ZnO, Ag (silver), and carbon nanotubes in PBS. In addition, mouse 257 
serum achieved a similar stabilizing effect to that achieved by pure mouse serum albumin 258 
(Bihari et al., 2008). Therefore, incubation of particles with plasma for 24h was the method 259 
used to stabilize the particles for subsequent studies.  260 
3.4.  Investigation of virus core protein expression after Huh7.5 cells transfection with 261 
J6/JFH1 HCV chimera:  262 
Fluorescence Microscopy was used to assess active replication in Huh7.5 cells transfected with 263 
HCV genomes. Expression of virus core protein was detected 48h after transfection of Huh7.5 264 
cells with J6/JFH1 and staining of the core protein using the primary antibody, C7-50 and 265 
secondary antibody- Alexa488 (Figure 2). The green fluorescence observed in Figure 2B 266 
represents expression of HCV core protein. Different cells were observed to have varying 267 
levels of Core expression (Figure 2B). A flow cytometry study (Figure 3) was also performed 268 
to assess virus transfection of Huh7.5 cells. Figure (3A) is the flow cytometry histogram, where 269 
X–axis represents Alexa-488 fluorescence intensity and it is indicative of labelled virus core 270 
protein and therefore it reflects the efficiency of virus transfection while Y-axis represents the 271 
number of events (number of cells).  272 
The red, black and blue histograms are blank1 (electroporated non-transfected Huh7.5 cells), 273 
blank2 (electroporated non-transfected Huh7.5 cells, treated with primary and secondary 274 
antibodies, to investigate if there a possibility of non-specific binding) and experimental 275 
(electroporated transfected Huh7.5 cells, treated with primary and secondary antibodies) 276 
respectively. As seen from the histogram, the red peak (Blank 1) represents the background 277 
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fluorescence of cells. It was found that there is a limited non-specific binding of antibodies as 278 
revealed by slight shift of red peak to a black peak (Blank 2) of higher fluorescence intensity 279 
along the Alexa-488 axis. Blue peak (Experimental sample to demonstrate virus replication) 280 
has the highest fluorescence signal of Alexa-488 and this is indicative of virus transfection 281 
success.  However, not all cells in the blue peak replicated virus equally and this could be 282 
demonstrated by division of blue peak into 3 sub-peaks: two small sub-peaks and a larger sub-283 
peak. A small sub-peak with a very low fluorescence signal ranging from 1 to 10 represents a 284 
cell population that did not replicate virus. The second small sub-peak and the larger sub-peak 285 
represent cell populations that replicated virus but with unequal efficiency, where the small 286 
sub-peak with signal fluorescence ranging from 150 to 10,000 along Alexa-488 axis represents 287 
the cell population with the highest efficiency of virus replication while the larger peak had a 288 
lower fluorescence intensity with signal intensity ranging from 10 to 150. 289 
 290 
Moving to flow cytometry graphs Figure 3 (B), (C), (D) representing Blank1, Blank2, and 291 
Experimental respectively. X-axis represent the Alexa-488 fluorescence intensity which is 292 
indicative of labelled virus core protein while Y-axis represent RBITC fluorescence intensity 293 
that is indicative of NP uptake. Each graph is subdivided into 4 quadrants where the lower left 294 
(LL) quadrant represents cells with a low fluorescence signal for both RBITC and labelled 295 
virus core protein. Moving from LL quadrant to the lower right (LR) quadrant indicates an 296 
increase of Alexa-488 fluorescence intensity that is indicative of virus transfection. As shown 297 
in Figure 3 (B), for blank1, almost all cells in the population occupied the LL quadrant with a 298 
very limited number of cells (0.26%) appearing in the LR quadrant. Figure 3 (C) represents 299 
blank2 cells where cells occupied the same quadrants as blank1 but more cells occupied LR 300 
(0.58) and this is indicative of slightly more cells with higher fluorescence intensity for Alexa-301 
488. This might reflect a non-specific binding due to treatment with primary and secondary 302 
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antibodies. Figure 3 (D), represents Experimental (transfected cells) where cells occupy both 303 
LL and LR quadrants but LR quadrant has a higher population of cells (13.9%) than both blank 304 
1 and blank 2. This demonstrated that virus transfection of Huh7.5 cells was successful due to 305 
higher number of cells with higher fluorescence intensity along Alexa-488 axis. However, as 306 
previously described in the flow cytometry histogram Figure 3 (A) that most cells are 307 
transfected with (J6/JFH1) but not all cells equally replicated the virus. The latter means that 308 
cells located in LL quadrant in graph (D) might contain some cells that are infected by Huh7.5 309 
cells but do not replicate efficiently enough to be detected in LR quadrant. Although, not all 310 
cells replicate virus equally, the transfected cells could be used to investigate the effect of virus 311 
transfection on the uptake of RBITC PGA NP.   312 
3.5. Confocal microscopy investigation of NP uptake by virus transfected Huh7.5 cells 313 
versus non-transfected cells:  314 
The time course of NP uptake into transfected cells was initially investigated by confocal 315 
microscopy (Figure 4). A, B, C and D images represent blue, green, red fluorescence channels 316 
and overlay of all channels respectively of a single plane image of transfected cells incubated 317 
with NP. The red fluorescence shows RBITC PGA NP. After 0.5 h incubation, red fluorescence 318 
was seen as fine dots distributed across the cells. With increasing incubation time, the number 319 
of fine dots first increased, and then larger bright patches of red fluorescence were seen after 320 
2h. By 4 h, there was a high level of both fine dots and patches.  Some red fluorescence patches 321 
of aggregated particles that were not associated with cells could also be seen (green arrows). 322 
A closer examination of the fluorescence distribution in the cells at different depth through the 323 
cells (different Z-stacks) by confocal microscopy is presented (Figure 5). The presence of red 324 
fluorescence in the plane of the section through the nucleus demonstrated an intracellular 325 
localisation of the particles. The appearance of these dots close to the peri-nuclear region 326 
together with an increase of the fluorescence intensity over incubation time suggested that 327 
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uptake of NP by cells was a continuous endocytic process where endosomes fused together to 328 
form late endosomes that are further fused to form lysosomes. It is generally accepted that most 329 
nano-particulates are taken up into cells by a variety of endocytic routes (Garnett and Kallinteri, 330 
2006). The physicochemical properties of NP and culture medium have a role on the interaction 331 
of NP with cells. PGA polymer has COOH group that should be in the anion form at the pH 332 
(7.4) of the culture medium and therefore RBITC PGA NP should carry negative charge as 333 
revealed by its zeta potential value measured at pH 7.4 (HEPES buffer, 10mM), (- 53.7 ± 334 
13.34). upon addition of RBITC PGA NP into the culture medium, protein -corona will be 335 
formed due to adsorption of different types of proteins and this should facilitate their uptake 336 
into cells. This is consistent with the literature where carboxylated polystyrene particles (1µm 337 
and 50nm) were taken up by alveolar type I cells (Fröhlich, 2012) . Park and his colleagues 338 
(Park et al., 2011) prepared gold NP functionalized with aromatic thiol derivatives to produce 339 
nanoparticles with a surface functional groups; NH2, COOH and OH. Functionalized gold NP 340 
were able to  adsorb proteins and had been taken up into A549 cells, adenocarcinomic human 341 
alveolar basal epithelial cells. It has been shown that there is not much difference of cell uptake 342 
due to different surface groups due to thick protein corona formed (Park et al., 2011). 343 
Therefore, it is the adsorbed layer of protein which affects NP uptake into cells rather than the 344 
charge of the naked particles. The uptake of RBITC PGA NP into Huh7.5 cells is also in 345 
agreement with a previous publication reporting that RBITC PGA NP are endocytosed and 346 
sorted into the lysosomal compartment of DAOY cells, a human medulloblastoma cell line 347 
(Meng et al., 2006). 348 
A single plane confocal microscopy image of NP taken up by virus-transfected cells compared 349 
to non-transfected cells after incubation for 4 h is presented (Figure 6). Non-transfected cells 350 
(Figure 6A) showed a relatively small number of fine dots of red fluorescence (orange arrow) 351 
that were associated with the cells compared to the significantly coarser and brighter dots seen 352 
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in the virus transfected cells (Figure 6B). The red fluorescence observed outside cells suggested 353 
some extracellular particle aggregation had occurred (green arrows).  354 
3.6. Flow Cytometry quantitative study of NP uptake by virus transfected and non-355 
transfected Huh7.5 cells: 356 
Flow cytometry of NP uptake into virus transfected and non-transfected Huh7.5 cells over 357 
different incubation times (0 to 4 h) was performed (Figure 7).  The X-axis represents Alexa-358 
488 fluorescence intensity (indicative of virus transfection) while the Y-axis represents RBITC 359 
fluorescence intensity (indicative of NP uptake).  The control graph shows that the majority of 360 
cells have a small shift along the X-axis demonstrating virus transfection. However, there are 361 
smaller populations with no increase or a little increase of fluorescence due to labelled core 362 
proteins of the virus as previously described in section 3.4. With increasing incubation time 363 
there was a progressive increase in fluorescence on the Y-axis representing NP uptake for the 364 
majority of the cell population in both transfected and non-transfected cells. For cells 365 
electroporated with HCV there was a significant population of cells with either no significant 366 
virus transfection or a low virus transfection in which no increase in NP fluorescence was 367 
observed. This might be due to an effect of virus RNA on cell vitality and this requires further 368 
investigation to determine whether these cells die or resume endocytosis at a later time. For 369 
non-transfected cells, there is very small population of cells showing low NP uptake. 370 
For better understanding of these results, it should be noted that the FACS had been set up to 371 
avoid the fluorescence spill over from RBITC channel into Alexa-488 channel and vice versa. 372 
The FACS had been set up using Huh7.5 cells of different properties in the following order; 373 
(1) Huh7.5 cells; non-transfected cells that were not treated with NP and they were used to 374 
blank the FACS. (2) a set of Huh7.5 cells; non-transfected and treated with NP to adjust red 375 
channel, (3) a set of Huh7.5 cells; transfected and not treated with NP to adjust green channel 376 
and (4) a set Huh7.5 cells; transfected and treated with NP to avoid spill over of fluorescence. 377 
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The data of fluorescence of Alexa-488 versus fluorescence of RBITC is presented (Figure 7) 378 
to show that the increased fluorescence from nanoparticle uptake, is related to the fluorescence 379 
from virus transfection. The relative proportion of cells (percentage of gated cells in each 380 
quadrant) involved in both virus transfection and nanoparticle uptake is also presented (Table 381 
2). The fluorescence from virus transfection is confined to the right half of the graph (Figure 382 
7) and (LR and UR in Table 2), and the fluorescence from particle uptake is found in the upper 383 
half of the graph (Figure 7) and (UL and UR in table 2).  Looking at percentages of cells in 384 
different quadrants (Table 2), we can see that most of the non-transfected cells did show uptake 385 
of nanoparticles (UL quadrant). In contrast, in the transfected cells there was a much lower 386 
percentage of cells in the UL quadrant, but also significant number of cells which show virus 387 
transfection and NP uptake (UR quadrant), and non-transfected and no NP uptake (LL 388 
quadrant).  These changes in the numbers of cells in these quadrants show that virus 389 
transfection did influence NP uptake.  It should also be noted, as explained earlier (Figure 3) 390 
that some of Huh7.5 cells replicate virus to a lower efficiency and might occupy the LL 391 
quadrant. From the above, we could speculate that the statistics of cells (% Gated cells) 392 
presented in Table 2 may underestimate the population of transfected cells in the LR quadrant 393 
and may overestimate the true percentage of cells in the LL quadrant because of this population 394 
of cells with a lower efficiency of transfection showing a low fluorescence of virus expression. 395 
Therefore, the NP uptake detected in UL quadrant for transfected cells might involve NP uptake 396 
not only due to non-transfected cells but also, virus transfected cells that replicate virus with a 397 
lower efficiency.  398 
Quantitative flow cytometry of NP uptake by virally transfected/non-transfected Huh7.5 cells 399 
is presented (Figure 8). NP uptake by virus transfected cells was significantly higher (P < 0.05) 400 
than non-transfected cells over all incubation time intervals, around 2 times more.  It is also 401 
interesting to note that the rates of uptake changed with time and the change in rates of uptake  402 
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 403 
differed between transfected and non-transfected cells.  In non-transfected cells the rate of 404 
uptake was constant for about 2h before the rate started to drop off.  However, in virus 405 
transfected cells there was a reduction in rate of uptake after a very rapid initial rate for the first 406 
hour of incubation.  After this initial period the rate of uptake showed a value similar to the 407 
initial rate of uptake in non-transfected cells and this rate is then maintained for the remainder 408 
of the 4h period. 409 
 410 
There was a slow rate of release of free RBITC from NP, and a control sample representing the 411 
amount of free dye associated with NP was also assessed. Free dye uptake was negligible after 412 
incubation with either virus transfected or non-transfected cells for 4 h and this demonstrated 413 
that fluorescence measured was due to actual NP uptake. The latter is in agreement with a 414 
Table 2: % Gated cells for virus transfected and non-transfected Huh7.5 cells 
Time %Gated for virus transfected Cells %Gated for virus non-transfected cells 
LL UL LR UR LL UL LR UR 
Experimental 99.34 0.03 0.58 0.05 - - - - 
0 31.38 51.64 4.30 12.67 27.14 72.53 0.11 0.22 
0.5 13.74 66.77 1.65 17.84 2.46 97.17 0.09 0.29 
1 14.15 67.82 1.60 16.42 1.47 98.11 0.09 0.32 
2 13.03 67.32 1.43 18.22 1.46 97.91 0.13 0.51 
3 11.10 69.18 0.82 18.90 1.09 98.46 0.07 0.38 
4 10.78 68.60 0.91 19.70 1.04 98.50 0.07 0.39 
Experimental: Cells electroporated in presence of HCV RNA and treated with 1ry and 2ry 
antibodies 
LL: Lower Left quadrant; low virus transfection, low NP uptake 
UL: Upper Left quadrant; low virus transfection, raised NP uptake 
LR: Lower Right quadrant; raised virus transfection, low NP uptake 
UR: Upper Right quadrant; raised virus transfection, raised NP uptake 
 
  
19 
 
previous publication that reported incubation of free dye (RBITC) with DAOY cells was 415 
associated with a very limited uptake compared to RBITC PGA NP (Meng et al., 2006). The 416 
staining for virus core protein required membrane permeabilization by saponin, which could 417 
potentially result in some leakage of NP. To account for this, control samples where cells were 418 
incubated with NP but not permeabilised was assessed. There was no statistically significant 419 
difference in uptake between permeabilised and non-permeabilised cells (Figure 8). The 420 
enhancement of NP uptake due to virus transfection might be explained by enhancement of 421 
one or more of the endocytic pathways that are responsible for NP uptake. This is consistent 422 
with the previous finding that adenovirus infection enhanced macro-pinocytosis process due to 423 
modulation of the cell cytoskeleton (Meier et al., 2002). The selective advantage of NP uptake 424 
into virus transfected hepatocytes as presented in the current study offers a significant benefit 425 
that might be attained by encapsulating antiviral agents for hepatic virus infection e.g. Hepatitis 426 
B and Hepatitis C. This concept could be further extended to other viruses, but further 427 
investigations is essential. 428 
 429 
4. Conclusions: 430 
Drug delivery using nanoparticles has been of interest since the early 1980s, but more recently 431 
there have been significant advances in drug delivery using biodegradable nanoparticles.  Much 432 
of this interest in nanoparticle delivery systems has its focus on cancer treatment because of 433 
the enhanced permeability and retention effect which provides a mechanism for selective 434 
delivery or increased targeting to tumour tissue.  We have additionally reported that under 435 
certain conditions PGA particles also showed an enhanced uptake into DAOY 436 
medulloblastoma cells in cells culture. There are other tissues where possibilities exist for 437 
targeting of nanoparticles and which may be exploited therapeutically.  One such possibility is 438 
delivery to the liver.  With this in mind we hypothesised that nanoparticle delivery may be a 439 
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good way to enhance delivery of antiviral agents to the liver while reducing the off-target 440 
accumulation and therefore side effects of antiviral agents in case of virus liver infections e.g. 441 
hepatitis B and C viruses. 442 
The current work demonstrated that Huh7.5 cells, a hepatic cell line transfected with HCV 443 
RNA showed a higher NP uptake than non-transfected cells. Virus transfection also resulted in 444 
changes in rates of uptake with time in comparison to non-transfected cells. These data suggest 445 
that polymer nanoparticles may provide a useful future delivery system for targeting virus 446 
infections of liver providing that antiviral agents could be sufficiently loaded into polymer 447 
nanoparticles. This approach could prove particularly effective in eradication of hepatitis B 448 
virus, where elimination of the HBV covalently closed circular DNA requires selective 449 
targeting of molecular therapies to latently infected hepatocytes. The application of NP directed 450 
therapies for other important viral diseases is an exciting possibility that requires further 451 
exploration. 452 
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